Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity

Immunome, Inc. (NASDAQ:IMNM)’s share price traded up 4.4% on Thursday after an insider bought additional shares in the company. The stock traded as high as $7.68 and last traded at $7.40. 229,972 shares were traded during mid-day trading, a decline of 73% from the average session volume of 836,334 shares. The stock had previously closed at $7.09.

Specifically, CEO Clay B. Siegall acquired 137,100 shares of Immunome stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. This represents a 20.47 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CTO Philip Tsai acquired 12,300 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at $280,386. The trade was a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In other Immunome news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $8.21 per share, with a total value of $57,470.00. Following the acquisition, the director now owns 23,615 shares in the company, valued at $193,879.15. This trade represents a 42.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on IMNM shares. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Stephens reiterated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital started coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Guggenheim lowered their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has an average rating of “Buy” and an average price target of $25.50.

Immunome Stock Down 4.0 %

The company has a market capitalization of $607.79 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. The stock has a 50 day moving average of $9.50 and a 200 day moving average of $11.33.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, sell-side analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of Immunome during the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC increased its position in Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome in the fourth quarter valued at approximately $95,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.